Bicara Therapeutics announces inducement grants

Bicara Therapeutics (BCAX) awarded an inducement grant on March 2, 2026 to one new employee under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employee received a non-qualified stock option to purchase 115,000 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $17.59 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on March 2, 2026. One-fourth of the shares vest on the first anniversary of the employee’s applicable start date, with the remaining shares vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date. The above-described award was granted outside of Bicara’s stockholder-approved equity incentive plans and is pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The award was approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).